Amsterdam, 2 - 3 March 2027
Schedule
Create your personal agenda –check the favourite icon
Mar 29:00
Conference pass
Implications of policy changes on market access
Plenary
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Mar 29:40
Conference pass
Keynote panel: The future of European JCA: From Assessments to National implementation
Plenary
Focus: Regional policy, HTA alignment, regulatory mechanics, and European market readiness.
What are the early takeaways from the initial JCA experiences, and what operational bottlenecks are HTA bodies currently facing?
How will unified European clinical assessments practically translate into national pricing, reimbursement, and economic decisions?
Where can Member States realistically harmonize their processes, and where will national differences remain?
How can the JCA framework be optimized to create a more predictable landscape for developers while accelerating equitable patient access across Europe
Anne Willemsen, Chair JCA Subgroup, Zorginstituut Nederland
Fabienne Bartoli, Inspector General, French National Authority for Health
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Antonella Cardone, CEO, Cancer Patients Europe
Rimma Berenstein, Deputy Head, Pharmaceuticals Department, G-BA
Mar 210:20
Conference pass
Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC
Plenary
Session led by: 
Mar 210:40
Conference pass
Keynote: Access by design: Embedding access into core development decisions - TBC
Plenary
Session led by: 
Mar 215:10
Conference pass
AI & Digitalization in HTA: Regulation, Transparency and Value
Interactive Panels
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 215:10
Conference pass
Financing Advanced Therapeutics: Next-Generation Payment Models for CAR-T and Gene Therapies
Interactive Panels
Caroline van der Meijden, Director, iMTA
Session led by: 
Mar 215:10
Conference pass
From silos to systems: HTA & Pharmaceutical companies & The Trump effect in an ever-changing world - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
Increasing the patient voice to inform decision making & improve equity globally in HTA
Interactive Panels
Adriana Robayo, Executive Director, Instituto de Evaluaci�n Tecnol�gica en Salud (IETS)
Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Mar 215:10
Conference pass
Launching Rare Disease Therapies in Europe and Globally: Aligning Evidence, Pricing, and Access from Day One
Interactive Panels
Moderator: Tomaso Piaggio, Head of International Market Access, Pricing & Policy, Alnylam Pharmaceuticals
Jennifer Quinn, Senior Director, Head of Market Access, Europe and International, Jazz Pharmaceuticals
Lorenzo Capretto, Head of HTA Strategy and Pricing, Global Rare Disease, Chiesi Farmaceutici SpA
Siew Ong, Senior Director, Cytokinetics
Mar 215:10
Conference pass
Market Access Under Pressure: Practical Solutions to Global Policy Shifts like MFN
Interactive Panels
Moderator: Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Anh Bourcet Nguyen, International Director, Government Affairs and Policy, Rare Diseases, AstraZeneca
Mar 215:10
Conference pass
Pre-launch success for orphan diseases in the JCA era - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
The Value of Joint Scientific Consultation (JSC): Optimizing Trial Design for EU-HTA Success
Interactive Panels
Stephanie Said, Coordination EU HTA Medicinal Products, G-BA
Stine Trolle, Senior Advisor, Danish Medicines Agency (DKMA)
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 215:10
Conference pass
Title TBC
Interactive Panels
Session led by:
Create your personal agenda –check the favourite icon
Mar 39:20
Conference pass
Keynote: Beyond the buzzwords: How market access professionals are using AI in practice - TBC
Plenary
Session led by: 
Mar 310:00
Conference pass
Panel: Staying Agile in a Shifting Landscape: Rethinking Global Market Access in the MFN era
Plenary
How are recent policy developments influencing pricing dynamics and launch sequencing?
Are companies becoming more selective in where and when they launch, and how does this differ for rare & specialty products vs mass-market therapies?
How do you manage pricing risk across interconnected markets without compromising long-term value?
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Marta Andreykiv, VP, Viatris
Moderator: Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 315:10
Conference pass
AI in market access: knowing when it’s the hero (and when it isn’t) - TBC
Interactive Panels
Session led by: 
Mar 315:10
Conference pass
Critical capabilities for leadership development: stakeholder management & influence
Interactive Panels
Moderator: Natalia Scherff, Leadership Coach, INSEAD, ICF PCC, Coach Scherff
Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 315:10
Conference pass
Health System Readiness for Breakout Medical Devices
Interactive Panels
Moderator: Georges André, President, StratPulse Partners
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 315:10
Conference pass
How EU JCA is shaping Vaccine Reimbursement Pathways
Interactive Panels
Nicolas Jamet, Global Pricing and Market Access Lead, GSK
Anna Vicere, Director, Access Policy & Public Affairs, Vaccines Europe
Mar 315:10
Conference pass
How to Build a Resilient-Launch Strategy
Interactive Panels
- Lessons learnt fromsuccessfullaunches
- Use of digital tools and AI to distinguish critical strategic signals from market noise to drive data-led launch strategies
- Generating the right evidence for productlaunches.
Jolanda Koenders, Head lx, Takeda
Bruno Cherel, Senior Director, Head of Pricing, Jazz Pharmaceuticals
Mar 315:10
Conference pass
Integrating market access into HEOR decisions
Interactive Panels
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Sophie Janssens, Sr VP, Global Head of Patient Impact Maximization (GO), UCB
Karla Hernandez-Villafuerte, Senior Researcher, Health Economics, WifOR
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Mar 315:10
Conference pass
Lessons learnt from first JCA results, national experiences and comparison of national approaches for pricing & reimbursement decisions
Interactive Panels
Valentina Strammiello, Interim Executive Director, European Patients' Forum
Mar 315:10
Conference pass
Parallel trade, tendering and erosion: pricing across the full product lifecycle and impact of MFN
Interactive Panels
Aveline Godard, Head of Global Pricing & Tendering, Ferring
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Mar 315:10
Conference pass
Securing Fair Pricing and Reimbursement for Value-added Medicines
Interactive Panels
Thomas Grub, Director, Global Pricing and Market Access, Medac GmbH
Marta Andreykiv, VP, Viatris
Klara Marton, International Strategic Business Development Director, Egis Pharmaceuticals Plc
Mar 315:10
Conference pass
The Path to Faster & Sustainable Patient Access in Europe
Interactive Panels
Moderator: Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Noem Sain, EU Market Access Lead, UCB Pharma
Alessandro Monaco, General Manager, Oliba Healthcare and Pharma
Mihai Rotaru, Director, Market Access, EFPIA
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
last published: 06/Jul/26 15:55 GMT
Get Involved
Sponsorship & Exhibition Sales
Oliver Hersey-Swan
oliver.hersey-swan@terrapinn.com
Speaking Opportunities
Isla Sutherland
isla.sutherland@terrapinn.com
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events